TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
The new capital is expected to fund the company through 2029
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
New facility in Sector 51 offers advanced, affordable, and patient-centric dialysis services for NCR patients
Safety was equally impressive. ENV-294 was well tolerated
In his new role, Saran will spearhead the end-to-end launch framework for innovation-led portfolio
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
Paid-up equity capital rises to Rs 973.19 crore following allotment to eligible employees
Subscribe To Our Newsletter & Stay Updated
